ArticlePloS one2026
Impact of COVID-19 on new pharmacotherapy for insomnia: A matched cohort study using the national insurance claims database in Japan.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic has profoundly affected impacted both physical and mental well-being. This matched cohort study investigated the effects of COVID-19 on pharmacological treatments for insomnia, using Japan's National Insurance Claims Database.
methodsData were matched by age, sex, Charlson Comorbidity Index (CCI) score, and enrollment month. Incidence rate ratios (IRR) and incidence rate differences (IRD) were calculated and compared for insomnia medication initiation, and subgroups based on age and sex categories. Sensitivity analyses were conducted for segmented intervals of 0-4, 5-12, and after 12 months.
resultsThe study included approximately 2 million pairs, predominantly women (59.4%), with a median follow-up of 7 months (Interquartile range, 4-12). Initiation of any insomnia medications occurred 77626 and 43142 times in the COVID-19 and control groups, respectively. IRR for new prescriptions was 1.7 times higher in the COVID-19 group (IRR: 1.71, 95% confidence interval [CI] 1.69-1.73), with an IRD of 1,634 events per 1,000,000 person-months (95%CI: 1599-1669). Non-Benzodiazepines and short-acting Benzodiazepines had the highest excess burdens among secondary endpoints. The risk was observed in all age categories, even in under 20 years (younger individuals: IRR: 1.46 95%CI 1.39-1.53, IRD: 380, 95%CI 333-427). Sensitivity analysis confirmed an increased risk over time, even after 12 months (IRD: 752, 95%CI 662-842).
conclusionCOVID-19 significantly associates with an elevated risk of insomnia medication initiation, emphasizing the necessity for mental health support in post-COVID-19 care. This study offers insights into the pandemic's influence on pharmacological treatment practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.